Onintza Sagredo Selected Research

Onintza Sagredo Research Topics

Disease

11	Huntington Disease (Huntington's Disease) 03/2017 - 08/2007
9	Neurodegenerative Diseases (Neurodegenerative Disease) 11/2018 - 08/2007
4	Disease Progression 03/2017 - 01/2011
3	Myoclonic Epilepsies (Myoclonic Encephalopathy) 01/2022 - 01/2016
3	Seizures (Absence Seizure) 01/2022 - 01/2016
2	Febrile Seizures (Febrile Seizure) 01/2022 - 01/2020
2	Nervous System Diseases (Neurological Disorders) 01/2020 - 04/2012
2	Epileptic Syndromes 01/2020 - 01/2016
2	Inflammation (Inflammations) 01/2016 - 01/2013
2	Vomiting 02/2013 - 04/2012
2	Nausea 02/2013 - 04/2012
2	Gliosis 01/2013 - 05/2012
1	Brain Diseases (Brain Disorder) 11/2018
1	Hypoxia (Hypoxemia) 11/2018
1	Neurodevelopmental Disorders 11/2018
1	Drug Resistant Epilepsy 11/2018
1	Mitochondrial Diseases (Mitochondrial Disease) 03/2017
1	Neuroinflammatory Diseases 02/2013
1	Epilepsy (Aura) 02/2013
1	Schizophrenia (Dementia Praecox) 02/2013
1	Tauopathies 01/2013
1	Dementia (Dementias) 01/2013
1	Frontotemporal Dementia (Semantic Dementia) 01/2013
1	Motor Neuron Disease (Primary Lateral Sclerosis) 01/2013
1	Parkinsonian Disorders (Parkinsonism) 01/2013
1	Edema (Dropsy) 05/2012
1	Acquired Immunodeficiency Syndrome (AIDS) 04/2012
1	Neoplasms (Cancer) 04/2012
1	Brain Ischemia (Cerebral Ischemia) 12/2011
1	Feeding and Eating Disorders (Eating Disorder) 12/2009
1	Nerve Degeneration 11/2009
1	Basal Ganglia Diseases (Basal Ganglia Disease) 08/2007
1	Chronic Disease (Chronic Diseases) 08/2007
1	Parkinson Disease (Parkinson's Disease) 08/2007
1	Atrophy 08/2007

Drug/Important Bio-Agent (IBA)

10	CannabinoidsIBA 01/2020 - 08/2007
9	CannabidiolIBA 01/2022 - 08/2007
5	Neuroprotective AgentsIBA 05/2012 - 08/2009
4	nabiximols (Sativex)IBA 03/2017 - 09/2011
4	Cannabinoid Receptors (Cannabinoid Receptor)IBA 01/2015 - 11/2009
3	Proteins (Proteins, Gene)FDA Link 01/2016 - 04/2012
3	CB2 Cannabinoid ReceptorIBA 01/2013 - 04/2008
2	Sodium Channels (Sodium Channel)IBA 01/2022 - 01/2020
2	EndocannabinoidsIBA 01/2020 - 01/2016
2	malonic acid (malonate)IBA 05/2012 - 08/2009
1	caryophylleneIBA 01/2022
1	Pentylenetetrazole (Metrazol)IBA 01/2020
1	Protons (Proton)IBA 03/2017
1	Calcium Channels (Calcium Channel)IBA 01/2016
1	Cytokine Receptors (Cytokine Receptor)IBA 01/2016
1	Peroxisome Proliferator-Activated Receptors (PPAR)IBA 01/2016
1	cannabigerolIBA 01/2015
1	Calcium Gluconate (CBG)IBA 01/2015
1	AntioxidantsIBA 02/2013
1	Anticonvulsants (Antiepileptic Drugs)IBA 02/2013
1	AntiemeticsIBA 02/2013
1	Antipsychotic Agents (Antipsychotics)IBA 02/2013
1	Anti-Anxiety Agents (Anxiolytics)IBA 02/2013
1	Dopamine (Intropin)FDA LinkGeneric 01/2013
1	Amyloid (Amyloid Fibrils)IBA 01/2013
1	Glutathione Disulfide (GSSG)FDA LinkGeneric 01/2013
1	Nerve Growth Factors (Neurotrophins)IBA 05/2012
1	Nitric Oxide Synthase Type II (Inducible Nitric Oxide Synthase)IBA 05/2012
1	Insulin-Like Growth Factor I (IGF-1)IBA 05/2012
1	Dronabinol (THC)FDA LinkGeneric 04/2012
1	polyglutamineIBA 04/2012
1	nabilone (Cesamet)FDA Link 04/2012
1	Analgesics (Analgesic Drugs)IBA 04/2012
1	imidazoleIBA 12/2011
1	3- (5- nitrofuryl)- 7- (5- nitrofurfurylidene)- 3,3a,4,5,6,7- hexahydro- 2H- indazoleIBA 12/2011
1	Brain-Derived Neurotrophic Factor (BDNF)IBA 01/2011
1	AmidesIBA 12/2009
1	Fatty Acids (Saturated Fatty Acids)IBA 12/2009
1	Mixed Function Oxygenases (Monooxygenases)IBA 12/2009
1	Quinolinic AcidIBA 11/2009
1	Cannabinoid Receptor AgonistsIBA 08/2009
1	ElementsIBA 04/2008
1	3-nitropropionic acidIBA 08/2007
1	Adenosine A2A Receptor (Adenosine A2A Receptors)IBA 08/2007

Therapy/Procedure

3	Therapeutics 01/2015 - 04/2012
1	Oral Administration 04/2012
1	Drug Therapy (Chemotherapy) 04/2012